SEC Company Response from Q (QCLS) — Dec 3, 2019
Q/C TECHNOLOGIES, INC. (QCLS) (CIK 0001321834)
Date: Dec. 3, 2019 · CIK: 0001321834 · Accession: 0001493152-19-018697
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234447
Letter
Re: Akers Biosciences, Inc.
December 3, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F. Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1 (Registration No. 333-234447), as amended - Concurrence in Acceleration Request
Ladies and Gentlemen:
H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), hereby concurs in the request by Akers Biosciences, Inc. that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to 9:00 A.M. (Eastern Time), or as soon as practicable thereafter, on December 5, 2019, or at such later time as the Registrant or its outside counsel, Ellenoff Grossman & Schole LLP, may orally request by telephone call to the staff that such Registration Statement be declared effective. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
Wainwright hereby represents that it is acting in compliance and will act in compliance with the provisions of Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above proposed offering.
Very
truly yours,
H.C.
WAINWRIGHT & CO., LLC
Show Raw Text
CORRESP
1
filename1.htm
December
3, 2019
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F. Street, N.E.
Washington,
D.C. 20549
Re:
Akers
Biosciences, Inc.
Registration
Statement on Form S-1 (Registration No. 333-234447), as amended - Concurrence in Acceleration Request
Ladies
and Gentlemen:
H.C.
Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, pursuant to Rule
461 under the Securities Act of 1933, as amended (the “Securities Act”), hereby concurs in the request by Akers
Biosciences, Inc. that the effective date of the above-referenced registration statement (the “Registration Statement”)
be accelerated to 9:00 A.M. (Eastern Time), or as soon as practicable thereafter, on December 5, 2019, or at such later time as
the Registrant or its outside counsel, Ellenoff Grossman & Schole LLP, may orally request by telephone call to the staff that
such Registration Statement be declared effective. Wainwright affirms that it is aware of its obligations under the Securities
Act in connection with this offering.
Pursuant
to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably
anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary
prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
Wainwright
hereby represents that it is acting in compliance and will act in compliance with the provisions of Rule 15c2-8 promulgated under
the Securities Exchange Act of 1934, as amended, in connection with the above proposed offering.
Very
truly yours,
H.C.
WAINWRIGHT & CO., LLC
By:
/s/
Mark Viklund
Name:
Mark
Viklund
Title:
Chief
Executive Officer
430
Park Avenue | New York, New York 10022 | 212.356.0500
Security
services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC